Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Executive Summary
Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.
You may also be interested in...
EU Approval Recommendation Secures Ibrance Domination
The EMA’s CHMP has recommended Ibrance for HR+/HER2- breast cancer and Pfizer may be able to establish a dominant position in the EU even quicker than it did in the US.
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review
Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.